List of Pemfexy drug patents

Pemfexy is owned by Eagle Pharms.

Pemfexy contains Pemetrexed.

Pemfexy has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Pemfexy are:

  • US7772209

Pemfexy was authorised for market use on 08 February, 2020.

Pemfexy is available in solution;intravenous dosage forms.

Pemfexy can be used as use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with mesothelioma; use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with non-squamous non-small cell lung cancer.

The generics of Pemfexy are possible to be released after 28 October, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604990 EAGLE PHARMS Crystalline forms of pemetrexed diacid and manufacturing processes therefor
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7772209 EAGLE PHARMS Antifolate combination therapies
May, 2022

(8 months ago)

Drugs and Companies using PEMETREXED ingredient

Market Authorisation Date: 08 February, 2020

Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with mesothelioma; Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with non-squamous non-small cell lung cancer

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in